Study Scrutinizes Smoking Cessation Drug Risk
The neuropsychiatric risks of smoking cessation drugs may have been overstated, according to an FDA-requested study. Varenicline (Chantix) and bupropion (Wellbutrin) were compared to the nicotine patch and placebo with regard to efficacy and side effects. Of the more than 8,100 patients who were randomized, roughly half had a history of psychiatric disorders. In the non-psychiatric cohort, the rate of neuropsychiatric adverse events were 1.3%, 2.2%, 2.5%, and 2.4% in the varenicline, bupropion, nicotine, and placebo groups, respectively. The rates in the psychiatric group were 6.5%, 6.7%, 5.2%, and 4.9%, respectively. Varenicline was the most effective modality in achieving smoking abstinence. The authors concluded, “The study did not show a significant increase in neuropsychiatric adverse events attributable to varenicline or bupropion relative to nicotine patch or placebo.” (Lancet published online April 22, 2016. doi: http://dx.doi.org/10.1016/S0140-6736(16)30272-0).
The neuropsychiatric risks of smoking cessation drugs may have been overstated, according to an FDA-requested study.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.